FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?

被引:20
|
作者
Pandey, Anuradha [1 ]
Kumar, Goru Santosh [1 ]
Kadakol, Almesh [1 ]
Malek, Vajir [1 ]
Gaikwad, Anil Bhanudas [1 ]
机构
[1] Birla Inst Technol & Sci Pilani, Mol Pharmacol Lab, Dept Pharm, Pilani Campus, Pilani 333031, Rajasthan, India
关键词
FoxO1; metabolic disorders; diabetes; diabetic complications; obesity; inhibitors; AS1842856;
D O I
10.2174/1573399811666150804104858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FoxO1, one of the most widely expressed sub-families of the winged helix forkhead factors, is biologically ` omni-functional' owing to its far-flung roles in metabolism, cell cycle, tissue differentiation and development and oxidative stress response. The knowledge of involvement of FoxO1 in metabolic disorders has long been there, but the potential target remained underutilized due to unavailability of specific and potent inhibitors. The review provides an insight into the role of FoxO1 in orchestrating metabolic diseases' pathogenesis (including diabetes, its secondary complications and obesity) and compiles the literature on FoxO1 inhibitors. The emergence of various natural molecules and synthesized small molecules like AS1842856 as FoxO1 inhibitors urges us to think further and decide the future course of drug development for the management of metabolic disorders.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 50 条
  • [21] FoxO1 Ablation Rescues Metabolic Stress-induced Cardiac Remodeling
    Battiprolu, Pavan K.
    Morales, Cyndi R.
    Baker, Lauren
    Pedrozo, Zully
    Li, Dan L.
    Nguven, Annie
    Jiang, Nan
    Shelton, John M.
    Gillette, Thomas G.
    Lavandero, Sergio
    Hill, Joseph A.
    CIRCULATION, 2013, 128 (22)
  • [22] Metabolic Stress-Induced Activation of FoxO1 Triggers Diabetic Cardiomyopathy
    Battiprolu, Pavan K.
    Hojayev, Berdymammet
    Jiang, Nan
    Wang, Zhao V.
    Luo, Xiang
    Iglewski, Myriam
    Shelton, John M.
    Gerard, Robert D.
    Rothermel, Beverly A.
    Gillette, Thomas G.
    Lavandero, Sergio
    Hill, Joseph A.
    CIRCULATION, 2011, 124 (21)
  • [23] miR-139 impacts FoxO1 action by decreasing FoxO1 protein in mouse hepatocytes
    Hasseine, Larbi Kamal
    Hinault, Charlotte
    Lebrun, Patricia
    Gautier, Nadine
    Paul-Bellon, Rachel
    Van Obberghen, Emmanuel
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 390 (04) : 1278 - 1282
  • [24] Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site - FOXO1 is a FOXO target gene
    Al-Mubarak, Bashayer
    Soriano, Francesc X.
    Hardingham, Giles E.
    CHANNELS, 2009, 3 (04) : 233 - 239
  • [25] Cytosolic FoxO1: alive and killing
    Medema, Rene H.
    Jaattela, Marja
    NATURE CELL BIOLOGY, 2010, 12 (07) : 642 - 643
  • [26] FoxO1: mute for a tuned metabolism?
    Cheng, Zhiyong
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2015, 26 (08): : 402 - 403
  • [27] FOXO1 modulates osteoblast differentiation
    Siqueira, Michelle F.
    Flowers, Stephen
    Bhattacharya, Rupa
    Faibish, Dan
    Behl, Yugal
    Kotton, Darrell N.
    Gerstenfeld, Lou
    Moran, Elizabeth
    Graves, Dana T.
    BONE, 2011, 48 (05) : 1043 - 1051
  • [28] FoxO1 breaks diabetic heart
    Nagao, Mototsugu
    Asai, Akira
    Oikawa, Shinichi
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (01) : 37 - 38
  • [29] Foxo1 in hepatic lipid metabolism
    Cheng, Zhiyong
    White, Morris F.
    CELL CYCLE, 2010, 9 (02) : 219 - 220
  • [30] Interactions of FOXO1 Truncations with DNA
    McDaniel, Brianyell
    Weatherspoon, Amber
    Haynes, Rashad
    Cherlin, Tess
    Mottamal, Madhusoodanan
    Johanson, Kelly
    FASEB JOURNAL, 2015, 29